Gemini Bioproducts, a supplier of cell culture reagents and a portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm, has formed an exclusive distribution agreement for Canada with Toronto-based FroggaBio. Starting immediately, customers in Canada will be able to purchase Gemini’s current and future products directly from FroggaBio.

Gemini expects the agreement to result in significant growth, after previously serving the Canadian market from its U.S. operations. Canadian researchers will now have wider access to Gemini’s human sera, fetal bovine sera, T-cell media, and other complementary products.

“We are very excited about this partnership,” said Don O’Neil, chief commercial officer, Gemini. “Canada is a strategically important market with major advances in science and medicine. With FroggaBio, we have found a partner that truly understands our products and will demonstrate them to the right audience.”

Moshe Kapelnikov, chief executive officer, FroggBio, said, “We have been looking to expand our cell culture offerings for some time. We have admired Gemini for its reputation as a high-quality supplier to many of the top institutions in the U.S. and internationally for over 30 years. With the new products from Gemini and the burgeoning growth of the cell and gene therapy market, we expect to have many new satisfied customers.”